Resorcylic acid lactones having a C5-C6 cis double bond and a ketone at C7 and other compounds capable of Michael adduct formation are potent and stable inhibitors of a subset of protein kinases having a specific cysteine residue in the ATP binding site.
HEPATITIS B VIRUS REPLICATION INHIBITOR AND PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS B COMPRISING THE SAME
申请人:RIKEN
公开号:US20210332089A1
公开(公告)日:2021-10-28
The purpose of the invention is to develop and provide a novel therapeutic agent for hepatitis B that differs from the conventional therapeutic agent for hepatitis B in the mechanism of action, or target of interest.
Provided is an inhibitor of hepatitis B virus replication consisting of a spike region in the core protein of a hepatitis B virus, or an expression vector containing a nucleic acid encoding the same.
[EN] SPECIFIC KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES SPECIFIQUES